Literature DB >> 2002465

L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.

J P Vacca1, J P Guare, S J deSolms, W M Sanders, E A Giuliani, S D Young, P L Darke, J Zugay, I S Sigal, W A Schleif.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2002465     DOI： 10.1021/jm00107a050

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  9 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Pyrrolinone-based peptidomimetics. "Let the enzyme or receptor be the judge".

Authors:  Amos B Smith; Adam K Charnley; Ralph Hirschmann
Journal:  Acc Chem Res       Date:  2010-12-22       Impact factor: 22.384

3.  Target repurposing for neglected diseases.

Authors:  Michael P Pollastri; Robert K Campbell
Journal:  Future Med Chem       Date:  2011-08       Impact factor: 3.808

4.  Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles.

Authors:  N E Kohl; R E Diehl; E Rands; L J Davis; M G Hanobik; B Wolanski; R A Dixon
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

5.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.

Authors:  S Kageyama; T Mimoto; Y Murakawa; M Nomizu; H Ford; T Shirasaka; S Gulnik; J Erickson; K Takada; H Hayashi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.

Authors:  M J Otto; C D Reid; S Garber; P Y Lam; H Scarnati; L T Bacheler; M M Rayner; D L Winslow
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

7.  In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.

Authors:  M J Otto; S Garber; D L Winslow; C D Reid; P Aldrich; P K Jadhav; C E Patterson; C N Hodge; Y S Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

8.  In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations.

Authors:  S Kageyama; J N Weinstein; T Shirasaka; D J Kempf; D W Norbeck; J J Plattner; J Erickson; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 9.  Viral proteases as targets for chemotherapeutic intervention.

Authors:  C U Hellen; E Wimmer
Journal:  Curr Opin Biotechnol       Date:  1992-12       Impact factor: 9.740
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.